Stockscreener 앱 받기
2.91
0.69%
0.02
시장 영업 전:
2.98
0.07
+2.41%
전일 마감가:
$2.89
열려 있는:
$2.92
하루 거래량:
762.72K
Relative Volume:
0.69
시가총액:
$381.68M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-1.341
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
+7.78%
1개월 성능:
+0.34%
6개월 성능:
-45.15%
1년 성능:
-55.23%
1일 변동 폭
$2.83
$3.03
1주일 범위
$2.75
$3.03
52주 변동 폭
$2.56
$9.77
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.91 | 381.68M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Top 11 CRISPR Stocks to Invest In - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
Prime Medicine Files for Resale of 11 Million Shares - Marketscreener.com
Prime Medicine initiated with an Outperform at JMP Securities - MSN
Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Fmr LLC Sells 184,541 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com Canada
Prime Medicine stock a top pick for gene editing, says JMP Securities - Investing.com Canada
Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat
Intech Investment Management LLC Acquires Shares of 14,102 Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine (NYSE:PRME) Earns Buy Rating from Guggenheim - Defense World
Vestal Point Capital LP Purchases 620,000 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
Oppenheimer & Co. Inc. Has $69,000 Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
GSA Capital Partners LLP Invests $383,000 in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.25 - Defense World
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prime Medicine Inc 주식 (PRME) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 15 '24 |
Buy |
6.25 |
3,200,000 |
20,000,000 |
3,200,000 |
| ARCH Venture Partners X, LLC | 10% Owner |
Feb 15 '24 |
Buy |
6.25 |
3,200,000 |
20,000,000 |
3,200,000 |
4.81%
자본화:
|
볼륨(24시간):